论文部分内容阅读
目的探讨非小细胞肺癌患者血清人类表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)和环氧化酶-2(cyclooxygenase-2,COX-2)水平相关性及与预后的关系。方法非小细胞肺癌患者221例(观察组)与肺部良性疾病患者41例(对照组),2组采用双抗体夹心ELISA法检测血清HER-2和COX-2水平,分析二者相关性及与生存时间的关系。结果观察组HER-2和COX-2水平明显高于对照组(P<0.05);观察组HER-2阳性表达者中位生存时间(48.7周)较HER-2阴性表达者(62.3周)短;COX-2阳性表达者中位生存时间(67.0周)较COX-2阴性表达者(83.1周)短(P<0.05);观察组HER-2与COX-2水平呈正相关(r=0.717,P=0.007);观察组HER-2和COX-2水平不是影响预后的独立危险因素,但二者联合检测可预测患者预后(OR=1.5,95%CI:1.08~2.09)。结论非小细胞肺癌与HER-2和COX-2阳性表达明显相关,二者联合检测有助于非小细胞肺癌的预后评估。
Objective To investigate the correlation between serum levels of human epidermal growth factor receptor-2 (HER-2) and cyclooxygenase-2 (COX-2) in patients with non-small cell lung cancer Prognosis of the relationship. Methods 221 cases of non-small cell lung cancer (observation group) and 41 cases of benign pulmonary disease (control group), two groups were detected by double antibody sandwich ELISA HER-2 and COX-2 levels, the correlation between the two And the relationship between survival time. Results The HER-2 and COX-2 levels in the observation group were significantly higher than those in the control group (P <0.05). The median survival time (48.7 weeks) in the HER-2 positive group was shorter than that in the HER-2 negative group ; The median survival time (67.0 weeks) in COX-2 positive patients was shorter than that in COX-2 negative patients (83.1 weeks) (P <0.05); HER-2 was positively correlated with COX- P = 0.007). The levels of HER-2 and COX-2 in the observation group were not independent risk factors for prognosis. However, the combination of HER-2 and COX-2 in the observation group could predict the prognosis of patients (OR = 1.5,95% CI: 1.08-2.09). Conclusions Non-small cell lung cancer is positively correlated with the positive expression of HER-2 and COX-2, and the combined detection of them can contribute to the prognosis evaluation of non-small cell lung cancer.